GEORGE S. HUGHES JR., M.D.; R. STEPHEN PORTER, PHARM.D.
This content is PDF only. Please click on the PDF icon to access.
To the editor: Primary pulmonary hypertension is fatal within several months to 3 years of diagnosis (1). Numerous agents have produced minimal hemodynamic improvement or change. Captopril, an inhibitor of angiotension-converting enzyme, has been successfully used in only one case in which improved cardiac output and a fall in both pulmonary and systemic vascular resistance were noted (2). However, other investigators found that captopril exerts its major effect on systemic vasculature with little or no effect on the pulmonary circuit (3). We report both short- and long-term beneficial effects of captopril in two cases.
Two patients had no underlying medical
HUGHES GS, PORTER RS. Captopril and Primary Pulmonary Hypertension. Ann Intern Med. 1983;99:569. doi: https://doi.org/10.7326/0003-4819-99-4-569_1
Download citation file:
Published: Ann Intern Med. 1983;99(4):569.
Copyright © 2020 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use